Verrica Pharmaceuticals (NASDAQ:VRCA) Stock Rating Upgraded by Zacks Research

Verrica Pharmaceuticals (NASDAQ:VRCA – Get Free Report) was upgraded by equities research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Separately, Wall Street Zen downgraded shares of Verrica Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $17.00.

Get Verrica Pharmaceuticals alerts:

Get Our Latest Report on Verrica Pharmaceuticals

Verrica Pharmaceuticals Stock Performance

Shares of VRCA stock opened at $7.15 on Monday. Verrica Pharmaceuticals has a one year low of $3.28 and a one year high of $9.82. The company’s 50-day moving average is $5.98 and its 200 day moving average is $6.29. The company has a market capitalization of $122.84 million, a price-to-earnings ratio of -4.53 and a beta of 1.54. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.45 and a current ratio of 2.59.

Verrica Pharmaceuticals (NASDAQ:VRCA – Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.14. The firm had revenue of $5.02 million for the quarter, compared to analysts’ expectations of $4.51 million. Sell-side analysts expect that Verrica Pharmaceuticals will post -2.24 EPS for the current fiscal year.

Institutional Trading of Verrica Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. State Street Corp increased its position in shares of Verrica Pharmaceuticals by 14.1% during the 4th quarter. State Street Corp now owns 23,481 shares of the company’s stock worth $195,000 after purchasing an additional 2,900 shares during the last quarter. Man Group plc acquired a new position in Verrica Pharmaceuticals in the 4th quarter valued at about $94,000. Quadrature Capital Ltd acquired a new position in Verrica Pharmaceuticals in the 4th quarter valued at about $99,000. Bridgeway Capital Management LLC acquired a new position in Verrica Pharmaceuticals in the 3rd quarter valued at about $52,000. Finally, Beck Mack & Oliver LLC acquired a new position in Verrica Pharmaceuticals in the 4th quarter valued at about $100,000. 42.45% of the stock is currently owned by institutional investors.

Verrica Pharmaceuticals Company Profile

(Get Free Report)

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.

Further Reading

• Five stocks we like better than Verrica Pharmaceuticals
• Navy Catalyst Ignites Odysight’s Growth Engine
• AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
• Axon Surged After Earnings and Is Still Down Over 50% From Highs
• The Event That Could Redefine Apple’s Summer Rally

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.